Literature DB >> 16426869

The use of levetiracetam in refractory status epilepticus.

Nitin C Patel1, Ivan R Landan, Jeffrey Levin, Jerzy Szaflarski, Andrew N Wilner.   

Abstract

Six patients with status epilepticus (SE) of various etiologies refractory to at least two antiepileptic drugs (AEDs) had complete cessation of their seizures following administration of oral levetiracetam (LEV). Seizure types included convulsive, focal, and nonconvulsive status epilepticus. Effective doses of levetiracetam ranged from 500 to 3000 mg/day, achieving seizure control within 12-96 h. No significant adverse events were noted. Adjunctive levetiracetam should be considered for patients with status epilepticus unresponsive to initial therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16426869     DOI: 10.1016/j.seizure.2005.12.003

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  21 in total

1.  New treatment options in status epilepticus: a critical review on intravenous levetiracetam.

Authors:  Eugen Trinka; Judith Dobesberger
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

2.  Intravenous levetiracetam terminates refractory focal status epilepticus.

Authors:  Nicholas S Abend; Nicole Florance; Richard S Finkel; Daniel J Licht; Dennis J Dlugos
Journal:  Neurocrit Care       Date:  2009       Impact factor: 3.210

Review 3.  Recent developments in the diagnosis and treatment of status epilepticus.

Authors:  Megan Selvitelli; Frank W Drislane
Journal:  Curr Neurol Neurosci Rep       Date:  2007-11       Impact factor: 5.081

Review 4.  Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients.

Authors:  Elizabeth L Alford; James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

Review 5.  [Management of refractory status epilepticus from a neurologic and neuropediatric perspective].

Authors:  B Pohlmann-Eden; U Stephani; I Krägeloh-Mann; B Schmitt; U Brandl; M Holtkamp
Journal:  Nervenarzt       Date:  2007-08       Impact factor: 1.214

6.  Intravenous levetiracetam as treatment for status epilepticus.

Authors:  Sascha Berning; Frank Boesebeck; Andreas van Baalen; Christoph Kellinghaus
Journal:  J Neurol       Date:  2009-05-15       Impact factor: 4.849

7.  Experience with intravenous levetiracetam in status epilepticus: a retrospective case series.

Authors:  Gonzalo Gámez-Leyva; José Luis Aristín; Emilio Fernández; Julio Pascual
Journal:  CNS Drugs       Date:  2009-11       Impact factor: 5.749

Review 8.  Status epilepticus in children.

Authors:  Rani K Singh; William D Gaillard
Journal:  Curr Neurol Neurosci Rep       Date:  2009-03       Impact factor: 5.081

9.  Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.

Authors:  Jerzy P Szaflarski; Kiranpal S Sangha; Christopher J Lindsell; Lori A Shutter
Journal:  Neurocrit Care       Date:  2010-04       Impact factor: 3.210

10.  Intravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures.

Authors:  Nicholas S Abend; Heather M Monk; Daniel J Licht; Dennis J Dlugos
Journal:  Pediatr Crit Care Med       Date:  2009-07       Impact factor: 3.624

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.